Details

Project TitleTargeted Contrast Agents for Magnetic Resonance Imaging of Steroid Hormone-Related Diseases
Track Code2008-067
Short Description

Cell-permeable steroid hormone-targeted magnetic resonance imaging contrast agents. 
#healthcare #mri #imaging 

Abstract

Northwestern researchers have synthesized Gd(III)-chelated steroids that target steroid hormone receptors, including progesterone, estrogen and androgen receptors. The compositions provide novel contrast agents for MRI diagnosis. The water soluble complexes are cell-permeable and label cells and tissues expressing the targeted receptor at lower in vitro and in vivo toxicity than the more hydrophobic ProGlo MRI agent. Receptor status can be used to diagnose, non-invasively, prevalent diseases, such as breast, ovarian, endometrial and prostate cancers, as well as a measure of receptor-positive or -negative status to determine the best course of treatment.  

 
TagsHEALTHCARE: MRI, HEALTHCARE: imaging
 
Posted DateMay 9, 2014 4:29 PM

Inventor(s)

Teresa Woodruff 
Thomas Meade 
Preeti Sukerkar 
Jiyoun Lee 

Applications

  • Diagnosis of common steroid-related diseases 
  • Determination of receptor-positive or receptor-negative tumor status 
  • Detection, characterization and monitoring of steroid-related diseases

Advantages

  • Non-invasive 
  • Enables targeted imaging 
  • Enables spatial and temporal imaging 

Publications

IP Status

Issued US Patent No: 8,580,231 

Contact Information

Zach Brown, PhD
Invention Associate
(p) 847-491-4629
(e) zachary.brown@northwestern.edu